Inovio Pharmaceuticals, listed on NASDAQ:INO, is a biotechnology company focused on developing DNA medicines for HPV-associated diseases, cancers, and infectious diseases. The company is set to release its quarterly earnings on August 12, 2025. Wall Street estimates an earnings per share (EPS) of -$0.63 and revenue of approximately $8.33 million for this period.
Despite the projected negative EPS, Inovio is anticipated to surpass earnings estimates, as highlighted by the market's close watch on the company's performance. The expected year-over-year increase in earnings, despite lower revenues, suggests potential operational improvements. Investors are keen to see if Inovio can deliver a positive EPS surprise, which could boost the stock price.
Inovio's financial metrics reveal challenges, with a negative P/E ratio of -0.00085, indicating losses relative to its share price. The price-to-sales ratio is high at 330, meaning investors pay $330 for every dollar of sales. This reflects high investor expectations despite current profitability issues.
The company's enterprise value to sales ratio is 198.43, showing a high valuation compared to revenue. The debt-to-equity ratio of 0.22 indicates a low level of debt, which is a positive sign for financial stability. Inovio's current ratio of 2.63 suggests a strong ability to cover short-term liabilities with short-term assets. This financial health metric provides some reassurance to investors, even as they await the upcoming earnings report and management's discussion of business conditions.
